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Abstract: Background: Searching through the COVID-19 research literature to gain actionable clin-
ical insight is a formidable task, even for experts. The usefulness of this corpus in terms of improving 
patient care is tied to the ability to see the big picture that emerges when the studies are seen in 
conjunction rather than in isolation. When the answer to a search query requires linking together 
multiple pieces of information across documents, simple keyword searches are insufficient. To an-
swer such complex information needs, an innovative artificial intelligence (AI) technology named a 
knowledge graph (KG) could prove to be effective. Methods: We conducted an exploratory litera-
ture review of KG applications in the context of COVID-19. The search term used was “covid-19 
knowledge graph”. In addition to PubMed, the first five pages of search results for Google Scholar 
and Google were considered for inclusion. Google Scholar was used to include non-peer-reviewed 
or non-indexed articles such as pre-prints and conference proceedings. Google was used to identify 
companies or consortiums active in this domain that have not published any literature, peer-re-
viewed or otherwise. Results: Our search yielded 34 results on PubMed and 50 results each on 
Google and Google Scholar. We found KGs being used for facilitating literature search, drug repur-
posing, clinical trial mapping, and risk factor analysis. Conclusions: Our synopses of these works 
make a compelling case for the utility of this nascent field of research. 
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1. Introduction 
Due to the truly global nature of the COVID-19 pandemic, there has been an explo-
sion of academic literature on this subject in 2020. Faced with a mountain of data, we often 
turn to machines for analysis. What we are really after is extracting knowledge from these 
data, and despite their prodigious computational power, machines are unable to under-
stand, let alone answer, our complex questions. Even for the most basic questions, the 
search has too often been reduced to keywords, which reduces the sophistication of the 
query, i.e., loss of semantics. A human easily knows the difference between “Which drugs 
reduce the severity of COVID-19” and “Which drugs increase the severity of COVID-19”, 
but for a purely keyword-based search with no semantics, this difference cannot be con-
veyed to a machine. Now imagine a question such as “Which are the top 3 drugs being 
trialed for treating COVID-19 in terms of total number of enrolled patients” or “For which 
clinical outcome is predictive modeling for COVID-19 most successful”? If a machine 
could answer such questions, it would significantly accelerate scientific progress by 
providing answers to complex questions that may today require many hours of reading, 
even by subject matter experts. A knowledge graph (KG) is an artificial intelligence (AI) 
innovation to bring us closer to this vision [1]. 
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We aimed to conduct a thorough review of how KGs have so far been used in the 
context of COVID-19. This review should facilitate the widespread use of the existing KGs, 
and allow researchers to identify the unmet clinical needs, and refocus efforts to produce 
graphs that actually add to the existing corpus, rather than merely duplicating efforts of 
other research groups. 
2. Materials and Methods 
Before delving into the methods used for this study, we would like to (1) emphasize 
that this is not a systematic review, but an exploratory literature review, and (2) explain 
the reason for making this choice. A defining feature of a systematic review is that it uses 
a repeatable analytical method to answer a well-defined research question. This translates 
to using databases such as PubMed, MEDLINE, Web of Science, and clinical trial regis-
tries, and having pre-defined inclusion criteria that should ideally be formulated into a 
study protocol and published before the review starts. Systematic reviews are a great way 
of synthesizing various information sources in a mature discipline to guide evidence-
based medicine. They are often meant to be an exhaustive summary of available evidence, 
where evidence is defined as peer-reviewed literature indexed in the databases mentioned 
above. A great example would be a systematic review of the clinical effectiveness of pro-
ton therapy. Since a systematic review is often meant to inform clinical practice, the inclu-
sion criteria are much stricter than what is permissible in an exploratory review. 
An exploratory review, by contrast, is not meant to follow a repeatable analytical 
method or be an exhaustive summary. It typically provides a broad overview of work that 
has been carried out in a certain research domain and uses this to define the scope of 
future research. In other words, it is meant to define research objectives rather than change 
or inform clinical practice. Almost every original research paper begins with a short ex-
ploratory review of the current state-of-the-art. By its very nature, KGs for COVID-19 is a 
new field of research. While peer-reviewed literature does exist in this field, there is work 
being carried out both in academia and in industry that has yet to be published in journals. 
Thus, using only indexing databases such as PubMed is an inadequate way to capture the 
current extent of the research. 
The aim of this review is to identify the different applications of KGs with respect to 
COVID-19, even if such research is not mature enough to have been published in peer-
reviewed journals that are indexed by PubMed, which is focused on biomedical journals. 
This includes peer-reviewed articles in non-indexed journals, peer-reviewed conference 
proceedings, non-peer-reviewed preprints, as well as projects that are described or docu-
mented on websites but do not have any published manuscript. For example, the first 
citation used in this paper cannot be found using PubMed, because the source, i.e., Har-
vard Data Science Review, published by MIT Press online, is not indexed on PubMed. 
Unlike PubMed, Google Scholar is not limited to clinical and biomedical journals, and 
includes conference proceedings, books, and reports, that are not included in Web of Sci-
ence or PubMed. Google Scholar searches the full text of articles but PubMed and Web of 
Science search only the citation, abstract, and tagging information. The superiority of 
Google Scholar over PubMed with respect to the ability to retrieve relevant articles using 
a quick search has been studied before [2]. The advantages of PubMed over Google 
Scholar, which mainly stem from PubMed using human curation, are less relevant for this 
review, because the sources identified by Google Scholar are curated by us before inclu-
sion in the results. Nonetheless, we included PubMed in our search strategy to widen the 
scope. It would be unacceptable to use Google Scholar for a systematic review because the 
process must be repeatable, and human judgement used for quality evaluation is subjec-
tive and thus not repeatable. However, for an exploratory review, this does not pose a 
problem, and using Google Scholar allows access to a larger number of sources, some-
times referred to as “grey literature”. An up-to-date comparison of these different search 
approaches from the perspective of a librarian can be found elsewhere [3]. 
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The search term used for finding original sources for this review was “covid-19 
knowledge graph”, and the search was conducted on 7 January 2021 using Google, Google 
Scholar, and PubMed. The reason for using Google in addition to Google Scholar was to 
identify companies or consortiums that are working in this field but have not published 
any literature, peer-reviewed or otherwise. The first five pages of results were considered 
in both these platforms. Domain expertise was used to reduce this to unique sources, 
which were then used to obtain the results. This reduction consisted of removing dupli-
cates, verification of the relevance, and qualitative assessment of the rigor of publicly ac-
cessible work, whether in the form of articles or websites. The Results section constitutes 
a broad overview of the field; it separates the KGs for COVID-19 into clusters based on 
their intended use, and then briefly summarizes the information pertaining to each origi-
nal source. No KG-related paper that was discovered in the search was rejected from in-
clusion. There was no a priori decision on how many papers to include under each type 
of KG application. The Results section does not include any subjective opinions from us; 
such opinions are presented in the Discussion section. 
3. Results 
Our search yielded 34 results on PubMed and 50 results each on Google and Google 
Scholar, as the default number of results per page on both these platforms is 10. Table 1 
summarizes the papers we found and the main application they reported for the KGs they 
created. In our review, the papers are clustered into application groups depending on their 
KG application. These application groups and their associated papers are described in the 
rest of this section. In addition, our search also pointed us to the EU Datathon 2020 which 
organized two meetups of The Knowledge Graph Conference in April. The associated re-
cordings and slides can be found in the following link (accessed on 7 January 2021). We 
also found the CovidGraph project (https://covidgraph.org) (accessed on 7 January 2021), 
an interdisciplinary collaboration between academia and industry. In addition to the lit-
erature data, they connected information from genes and proteins and their function, us-
ing open-source knowledge bases such as the Gene Ontology and the NCBI Gene Data-
base. An important advantage of this project is that it uses Neo4j [4] for modeling, storing, 
and exposing the KG, which considerably simplifies adoption by a large body of data sci-
entists and app developers, as it is both powerful and intuitive. However, since there is 
no paper associated with this project yet, we cannot provide further detail in this review. 
Table 1. Summary of papers resulting from our literature curation. 
Authors Title Application 
Kejriwal Knowledge Graphs and COVID-19: Opportunities, Challenges, and 
Implementation 
KG overview 
Steenwinckel et al. Facilitating the analysis of COVID-19 literature through a knowledge 
graph 
Literature search 
Wise et al. 
COVID-19 knowledge graph: accelerating information retrieval and 
discovery for scientific literature Literature search 
Cernile et al. 
Network graph representation of COVID-19 scientific publications to aid 
knowledge discovery Literature search 
Michel et al. COVID-on-the-Web: Knowledge graph and services to advance COVID-
19 research 
Literature search 
Stebbing et al. COVID-19: combining antiviral and anti-inflammatory treatments Drug repurposing 
Wang et al. 
COVID-19 literature knowledge graph construction and drug 
repurposing report generation Drug repurposing 
Domingo-Fernandez et 
al. 
COVID-19 Knowledge Graph: a computable, multi-modal, cause-and-
effect knowledge model of COVID-19 pathophysiology Drug repurposing 
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Hsieh et al. 
Drug Repurposing for COVID-19 using Graph Neural Network with 
Genetic, Mechanistic, and Epidemiological Validation Drug repurposing 
Zhou et al. Artificial intelligence in COVID-19 drug repurposing Drug repurposing 
Chen et al. Coronavirus knowledge graph: A case study Multi-purpose 
Reese et al. KG-COVID-19: a framework to produce customized knowledge graphs 
for COVID-19 response 
Multi-purpose 
Ostaszewski et al. COVID-19 Disease Map, a computational knowledge repository of SARS-
CoV-2 virus–host interaction mechanisms 
Multi-purpose 
Bettencourt-Silva et al. Exploring the Social Drivers of Health During a Pandemic: Leveraging 
Knowledge Graphs and Population Trends in COVID-19 
Risk factor discovery 
3.1. Knowledge Graphs for Literature Search 
We found four articles that used KGs to facilitate the literature search. In the first 
paper by Steenwinckel et al. [5], the Kaggle dataset of 63,000 + papers (also known as 
CORD-19 [6], released to allow recent advances in natural language processing (NLP) and 
other AI techniques to generate new insights to fight the pandemic) was used to create a 
KG. The authors started with a summary of initiatives by other research groups who are 
using the same dataset, identifying the CovidGraph project as the largest such initiative. 
The authors then discussed the steps needed to construct their KG. In the CORD-19 da-
taset, information about each paper is provided as a CSV file. For over 51,000 of these 
papers, JSON files exist, containing information about the authors, the content, and the 
other cited studies. To semantically enrich the data, the authors mapped them to the re-
source description framework (RDF) using the RDF mapping language (RML), which was 
convenient because the initial data were already structured (CSV and JSON). Before the 
conversion from JSON to RDF, the JSON files were extended to include additional infor-
mation from external resources, including DBpedia [7], BioPortal [8], CrossRef [9], and 
ORCID [10].  
To make the transformation from JSON to RDF, a mapping document was created 
that contained rules on how each element in the JSON can be mapped on a corresponding 
semantic output value. The mapping document was created with YARRRML, a human-
readable text-based representation that can be used to represent RML rules [11]. This 
YARRRML document was then converted to an RML document by using the YARRRML 
Parser. The reason for using the intermediate YARRRML step instead of writing RML 
rules directly was because YARRRML, being human-readable, allows other researchers to 
extend the mapping documents with less effort and without needing expertise in semantic 
web formats. The RMLMapper [12], using both the extended JSON files and the RML doc-
ument as input, produces a set of N-Triples for each paper. The authors concatenated all 
such N-Triple files to form a single KG. 
The authors then discussed the applications of such a KG, which we summarize in 
the rest of this paragraph. They state that current network analysis tools cannot handle 
different labeled edges that make up such a multi-relational KG. Thus, the KG needs to be 
converted to a regular directed graph by retaining only citation information to perform 
network analysis. Nodes of their converted graph represent the papers; graph edges rep-
resent citations from one paper to another. The interconnectedness of publications via ci-
tations can be revealed using clustering analysis. Node centrality analysis can identify 
publications that are influential with respect to COVID-19, rather than influential in gen-
eral, for which looking at number of citations would suffice; the centrality of a node can 
be quantified via different metrics. Machine learning cannot be directly applied to KGs. 
As a workaround, knowledge graph embeddings can be used, where KG components, 
including entities and relations, are embedded into continuous vector spaces. RDF2vec 
[13] is the most common technique to build such embeddings. Once converted into these 
vectors, one can search for nearest neighbors to find similar or related papers in a much 
more powerful way than a keyword search. These vectors can also be used for clustering 
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papers, which is more powerful than the network clustering analysis previously de-
scribed, which only uses citation links. 
The second paper, by Wise et al. [14], also uses the CORD-19 dataset, is a demonstra-
tion of Amazon Web Services AI, and is conceptually more advanced than the first paper. 
Unlike the first paper, the second paper does not support the FAIR (findable, accessible, 
interoperable, and reusable) principle, and does not make any of its code public. However, 
their KG is used to power a search engine (https://www.cord19.aws/) (accessed on 7 Jan-
uary 2021), which is available for public use. The authors provide a succinct definition of 
a KG: “Knowledge graphs (KGs) are structural representations of relations between real-
world entities where relations are defined as triplets containing a head entity, a tail entity, 
and the relation type connecting them.” Their KG contains five types of entities: paper 
(with attributes of title, publication date, journal, and digital object identifier (DOI) link), 
author (with attributes of first, middle, and last names), institution (with attributes of 
name, country, and city), concept, and topic. Figure 1 illustrates the directed property 
graph structure for a small subgraph of their KG. 
 
Figure 1. Visualization of a knowledge graph (KG). Paper entities (blue) connect to concepts (red), 
topics (light blue), and authors (gold) through directed relations. Authors connect to institutions 
(green). Reproduced with permission from Wise et al. [14]. 
Concept entity: They used their proprietary NLP system named Comprehend Medical 
Detect Entities V2 for medical language entity recognition and relationship extraction. 
Given the example text “Abdominal ultrasound noted acute appendicitis, recommend ap-
pendectomy followed by several series of broad spectrum antibiotics”, the system extracts 
Abdominal (Anatomy), ultrasound (Test Treatment Procedure), acute appendicitis (Med-
ical Condition), appendectomy (Test Treatment Procedure), and antibiotics (Medication) 
as recognized entities along with entity types and model confidence scores. Entity names, 
e.g., acute appendicitis, form concept entities while entity type and model confidence 
score are the entities’ attributes. Topic entity: They defined 10 topics using expert 
knowledge: Vaccines/Immunology, Genomics, Public Health Policies, Epidemiology, 
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Clinical Treatment, Virology, Influenza, Healthcare Industry, Lab Trials (human) and Pul-
monary Infections. Since manually labeling a topic model is inefficient, they manually la-
beled only a subset of the papers and used this to train a multi-label classifier, an extension 
of Latent Dirichlet Allocation termed Z-LDA, using the title, abstract and body text from 
each paper. The resulting classifier achieved an average F1-score of 0.92 with on average 
of 2.37 labels per document. To validate their topic model, they checked that generated 
topics of papers from Journal of Virology, e.g., virology, genomics, and lab-trials-human, 
were highly related to virology and the generated topics of papers from Journal of Vac-
cine, e.g., vaccines-immunology, were highly related to vaccinology. 
To curate their KG, they applied data normalization techniques which eliminated 
duplicate entities and noisy linkages. Denoising included thresholding on the confidence 
scores, pruning concepts that occur in less than 0.0001% of papers, and flagging concepts 
that appear in greater than 50% of papers for manual assessment. The KG was then used 
for two main tasks: information retrieval and article recommendations. For information 
retrieval, an example query “What papers discussing COVID-19 risk factors are most of-
ten cited by researchers within the CORD-19 dataset?” results in two steps: first, the arti-
cles which contain the risk factors as entities are retrieved, and then these articles are 
ranked based on citation counts within the dataset. The authors combined article semantic 
information with KG topological information to quantify similarity between articles and 
construct a similarity-based recommendation system: given a paper, the engine retrieves 
a list of top-k most similar papers using cosine distance. To capture semantic information, 
they used SciBERT [15] that has shown strong transfer learning performance on a wide 
variety of NLP tasks. To capture KG topological information, they generated vector em-
beddings for each paper by using the algorithm TransE [16] and Deep Graph Library 
Knowledge Embedding library (DGL-KE [17]). Besides finding similar papers to a given 
paper, the recommendation engine can also be used to identify the most popular papers, 
where popularity captures the number of occurrences of an individual paper in the top-5 
most similar items list for all papers in the dataset. 
The third paper, by Cernile et al. [18], also uses the CORD-19 dataset, and makes the 
dataset and visualizations publicly accessible via a webtool. They used proprietary NLP 
and AI engines which leverage a fast heuristic search algorithm and a knowledge-driven 
approach for concept identification, context determination, inferencing and extraction of 
corresponding values and units. The study used a collection of 10 general knowledge ba-
ses and nine domain-specific knowledge bases that were built using UMLS (Unified Med-
ical Language System) terms and updated with recently added terms specific to COVID-
19. Generic terms with little significance were determined, for example, “air”, “water” and 
“virus”, and removed from the set of extracted concepts. For each term found in a paper, 
a link was created to every other term in the same paper. The summation of these links 
over all papers determined the weight of a connection between any two terms: the number 
of papers linking the terms. Additional filtering was performed to refine the scope of the 
network and removal of noise to aid readability and navigation; for example, links with 
low weights were removed, as were links with terms that were disconnected from the rest 
of the network. Network nodes were colored based on the knowledge source, with the 
size of the nodes proportional to the frequency of each term and the connection weight, 
i.e., edge thickness, based on the number of associated papers. Four network graphs were 
generated using these extracted data: cardiological diseases, lung diseases, title network 
and treatment network (https://nlp.inspirata.com/networkvisualisations/treatmentnet-
work/) (accessed on 7 January 2021). 
The fourth paper, by Michel et al. [19], has grander ambitions than just a literature 
search. The COVID-on-the-Web Dataset created by this team can be put to other uses in 
the future, such as creating argumentative graphs which can be used by clinicians to ana-
lyze clinical trials for evidence-based decision-making. We categorized Michel et al. under 
a literature search as this is what is explicitly demonstrated in their current work. The 
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authors are strong proponents of open and reproducible science goals, and the FAIR prin-
ciples. Like the previous papers mentioned in this subsection, they also used the CORD-
19 dataset, and enriched it using DBpedia, BioPortal, and Wikidata to create the CORD-
19 Named Entities Knowledge Graph. In addition, all CORD-19 abstracts were analyzed by 
argumentative clinical trial analysis (ACTA [20]) and translated into RDF to create the 
CORD-19 Argumentative Knowledge Graph. ACTA is designed to analyze clinical trials to 
extract argumentative components and PICO (patients/population (P), intervention (I), 
control/comparison (C) and outcome (O)) elements. Finally, they provided several visual-
ization and exploration tools based on the Corese Semantic Web platform (https://pro-
ject.inria.fr/corese/) (accessed on 7 January 2021) and MGExplorer visualization library 
(https://github.com/frmichel/morph-xr2rml/) (accessed on 7 January 2021). 
ACTA retrieves the main claim(s) stated in the trial, the evidence linked to this claim, 
and the PICO elements. For a clinical trial, a claim is a concluding statement made by the 
author about the study outcome. It generally describes the relation of a novel treatment 
with respect to existing treatments, referred to as intervention arm and control arm, re-
spectively. An observation or measurement is evidence, consisting of side effects and the 
outcome. Two relation types can hold between argumentative components: attack and 
support, depending on whether a statement or observation is contradicting or justifying 
the proposition of the target component. The ACTA pipeline comprises four steps: (i) de-
tecting argumentative components, i.e., claims and evidence, (ii) predicting the relations 
between components, (iii) extracting PICO elements, and (iv) producing the RDF repre-
sentation of the arguments and PICO elements. 
To demonstrate the immediate clinical utility of Michel et al.’s ACTA framework 
(http://ns.inria.fr/acta/) (accessed on 7 January 2021), we applied it on 20 published papers 
that are all related to clinical trials for COVID-19 interventions. The papers were chosen by 
searching clinicaltrials.gov for all completed COVID-19 trials with available results, and 
then extending the search using The New England Journal of Medicine. The authors in-
cluded in ACTA the possibility to search for a (set of) abstract(s) directly on the PubMed 
catalogue through PubMed’s application programming interface (API). When the search 
results are shown, the user can select one or more abstracts to perform the argumentative 
analysis. The result is displayed to the user as an argumentative graph where the nodes are 
the premises and claims automatically detected in the abstract, together with their links. 
When the user hovers over a node, the textual content of the argumentative component is 
shown. The full text of the abstract is shown on the right side of the graph, where the user 
can highlight in different colors either the argumentative components or the PICO elements. 
The PICO identification results have been included in the Supplementary Material.  
3.2. Knowledge Graphs for Drug Repurposing 
We found five articles related to using KGs for drug repurposing, which is a tech-
nique of using existing drugs to treat emerging and challenging diseases, thereby reduc-
ing development timelines and overall costs. The first article, by Stebbing et al. [21], was 
published as a comment in Lancet Infectious Diseases near the beginning of the pandemic 
(1 April 2020). The authors had earlier described how BenevolentAI’s proprietary KG, 
queried by a suite of algorithms, enabled the identification of baricitinib, a numb-associ-
ated kinase (NAK) inhibitor, to suppress clathrin-mediated endocytosis and thereby in-
hibit viral infection of cells. In this work, they re-examined the affinity and selectivity of 
all the approved drugs in their KG to identify those with both antiviral and anti-inflam-
matory properties, since the host inflammatory response becomes a major cause of lung 
damage and subsequent mortality for severe cases of COVID-19. This yielded three can-
didates: baricitinib, fedratinib, and ruxolitinib. Other AI-algorithm-predicted NAK inhib-
itors included a combination of the oncology drugs sunitinib and erlotinib, shown to re-
duce the infectivity of a wide range of viruses. However, sunitinib and erlotinib would be 
difficult for patients to tolerate at the doses required to inhibit NAK. Baricitinib emerged 
as the best choice, especially given its once-daily oral dosing and acceptable side-effect 
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profile. In addition, the potential for combination therapy with baricitinib was high, in-
cluding combining baricitinib with the direct-acting antivirals (lopinavir or ritonavir and 
remdesivir) currently being used in the COVID-19 outbreak to reduce viral infectivity, 
viral replication, and the aberrant host inflammatory response. A trial of baricitinib plus 
remdesivir has already been conducted and was superior to remdesivir alone in reducing 
recovery time and accelerating improvement in clinical status [22]. 
The second article, by Wang et al. [23], used KGs for drug repurposing report gener-
ation. For a given drug, such a report consists of 11 typical questions they identified: (1) 
current indication: what is the drug class? What is it currently approved to treat? (2) Mo-
lecular structure; (3) mechanism of action, e.g., inhibits viral entry, replication; (4) Was the 
drug identified by manual or computation screen? (5) Who is studying the drug? 
(Source/lab name); (6) in vitro data, e.g., cell line used, assays run, viral strain used, cyto-
pathic effects, toxicity, LD50, dosage response curve; (7) animal data, e.g., what animal 
model, LD50, dosage response curve; (8) ongoing clinical trial data, e.g., what phase, fa-
cility, target population, dosing, intervention; (9) funding source; (10) has the drug shown 
evidence of systemic toxicity? (11) List of relevant sources to pull data from. The summary 
of their framework can be seen in Supplementary S1. 
They built a multimedia KG by combining (1) coarse-grained text knowledge extrac-
tion, (2) fine-grained text entity extraction, (3) image processing and cross-media entity 
grounding, and (4) KG semantic visualization. A KG constructed after just step (1) can be 
seen in Figure 2. A demonstration of steps (2) and (3) can be seen in Figure 3 and Supple-
mentary S2 respectively. Step (4) enhances the exploration and discovery of the infor-
mation in the KG by allowing user interactivity that surpasses directed keyword searches 
or simple unigram word cloud or heatmap displays. Several clinicians and medical school 
students in their team reviewed the drug repurposing reports for three drugs that were 
used as a case study for the paper (benazepril, losartan, and amodiaquine), and also the 
KGs connecting 41 drugs and COVID-19-related chemicals/genes. Preliminary results 
show that most of their output was informative and valid. 
 
Figure 2. Constructed KG connecting losartan (candidate drug in COVID-19) and cathepsin L 
pseudogene 2 (gene related to coronavirus). Reproduced with permission from Wang et al. [23]. 
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Figure 3. Example of fine-grained entity extraction. Reproduced with permission from Wang et al. [23]. 
The third article, by Domingo-Fernandez et al. [24], created a KG that is a cause-and-
effect knowledge model of COVID-19 pathophysiology, which could then be applied for 
drug repurposing. The authors point out that although KGs were originally developed to 
describe interactions between entities, novel machine learning techniques can generate 
latent, low-dimensional representations of the KG which can then be utilized for down-
stream tasks such as clustering or classification. For the creation of the KG, scientific liter-
ature related to COVID-19 was retrieved from open access and freely available journals: 
PubMed, Europe PMC, and additional COVID-19 specific corpuses such as LitCovid. This 
corpus was then filtered based on available information about potential drug targets for 
COVID- 19, biological pathways in which the virus interferes to replicate in its human 
host, and information on the various viral proteins along with their functions. Finally, the 
articles were prioritized based on the level of information that could be captured in the 
modeling language used to build the KG. Evidence text from the prioritized corpus was 
manually encoded in biological expression language (BEL) as a triple including metadata 
about the nodes and their relationships as well as corresponding provenance and contex-
tual information. BEL involves encoding mechanistic information such as protein–protein 
interactions, observed correlations between phenotypes and molecules, or effect of drugs 
on a given target. Therefore, only BEL encodable articles were selected. The authors ex-
plained in the Supplementary Material why they favored this manual curation over a text-
mining approach, arguing that the manual approach provides better quality in terms of 
contextualization, i.e., finding the proper relation between two entities due to the com-
plexity of scientific writing, and the understandability of the KG. They mentioned the 
possibility of using a semi-automatic pipeline to combine the advantages of manual cura-
tion and text-mining. 
Their KG summarizes mechanistic information on COVID-19 published in 160 original 
research articles. As described in their publication, the COVID-19 KG incorporates 4016 
nodes, covering 10 entity types (e.g., proteins, genes, chemicals, and biological processes) 
and 10,232 relationships (e.g., increases, decreases and association). They mentioned that 
given the selected corpora, these cause-and-effect relations primarily denote host–pathogen 
interactions as well as comorbidities and symptoms associated with COVID-19. Further-
more, the KG contains molecular interactions related to host invasion (e.g., spike glycopro-
tein and its interaction with the host via receptor ACE2) and the effects of the downstream 
inflammatory, cell survival and apoptosis signaling pathways. The authors have identified 
over 300 candidate drugs currently being investigated in the context of COVID-19, including 
proposed repurposing candidates and drugs under clinical trial. 
The fourth paper, by Hsieh et al. [25], aimed to discover repurposable drugs by inte-
grating multiple SARS-CoV-2 and drug interactions, deep graph neural networks (GNN), 
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and in vitro/population-based validations. They collected all the available drugs (n = 3635) 
involved in COVID-19 patient treatment through the Comparative Toxicogenomics Data-
base. The candidate drugs can be divided into two broad categories: those that can directly 
target the virus replication cycle, and those based on immunotherapy approaches either 
aimed to boost innate antiviral immune responses or to alleviate damage induced by 
dysregulated inflammatory responses. They built a SARS-CoV-2 KG based on the inter-
actions among virus baits, host genes, drugs, and phenotypes. The graph had four types 
of nodes and five types of edges based on the interactions. The four types of nodes include 
27 virus baits, 5677 unique host genes, 3635 drugs, and 1285 phenotypes. The five types 
of edges include 330 virus–host protein–protein interactions, 13,423 pairwise genes on the 
same pathway, 16,972 drug-target pairs, 1401 gene–phenotype pairs, and 935 drug–phe-
notype pairs. 
A GNN approach was used to derive the candidate drug’s representation based on 
the biological interactions. To justify their approach, the authors explained that in tradi-
tional network analysis, network proximity is defined with direct interactions, thus a 
node’s local role (e.g., neighbors, edge directions) and global position (e.g., overall topol-
ogy or structure) are less considered. GNNs derive a vectorized representation (i.e., em-
bedding) of nodes, edges, or whole graphs. The graph node embeddings used by a GNN 
can preserve the node’s local role and global position in the graph via iterative and non-
linear message passing and aggregation. A GNN learns the structural properties of the 
neighborhood and the graph’s overall topological structure. The graph embedding 
method used was the variational graph autoencoder with multi-relational edges. The au-
thors prioritized the candidate drugs using clinical trial history, and then validated them 
with their genetic profiles, in vitro experimental efficacy, and electronic health records. 
The top 22 drugs included azithromycin, atorvastatin, aspirin, acetaminophen, and albut-
erol. They further pinpointed drug combinations that may synergistically target COVID-
19, including hydroxychloroquine plus melatonin. 
The fifth article, by Zhou et al. [26], is a review article for Lancet Digital Health. In 
the review, the authors introduced guidelines on how to use various forms of AI for ac-
celerating drug repurposing, with COVID-19 as an example. With regard to KGs in par-
ticular, they mention that KGs can be reduced to low-dimensional feature vectors, and 
using the feature vectors of drugs and diseases, one can then measure their similarities 
and thus identify effective drugs for a given disease. One challenge they identify for the 
graph embedding method is scalability. The number of entities in a medical KG could be 
as many as several million. They mention that several systems have been specifically de-
signed for learning representations from large-scale graphs (e.g., GraphVite [27]). The au-
thors identified two works which evaded our search strategy: Gysi et al. ([28], which did 
not use the term knowledge graph in the paper) and Zeng et al. [29]. Zeng et al.’s KG in-
cluded 15 million edges across 39 types of relationships connecting drugs, diseases, pro-
teins, genes, pathways, and expressions of genes and proteins from a large scientific cor-
pus of 24 million PubMed publications. Using Amazon Web Services’ computing re-
sources and graph representation learning techniques (DGL-KE, mentioned earlier in this 
paper in the context of literature search), they identified 41 repurposable drug candidates 
including dexamethasone, thalidomide, and melatonin whose therapeutic associations 
with COVID-19 were validated by transcriptomic and proteomics data in SARS-CoV-2-
infected human cells and data from ongoing clinical trials. 
3.3. Knowledge Graphs for Clinical Trials 
The pre-eminent effort to synthesize the results of clinical trials related to the preven-
tion and treatment of COVID-19 is the COVID-NMA initiative (https://covid-nma.com/) 
(accessed on 25 March 2021). This project aims to provide a complete, high-quality, and 
up-to-date synthesis of evidence as soon as results are available as well as a living map-
ping of registered randomized controlled trials. The vast majority of work involved in 
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curating the database is carried out by human volunteers. This synthesis will allow evi-
dence-based decision-making and planning of future research. We would like to mention 
that this initiative cannot be classified as a KG in the AI sense, because the concept of 
triples, which is central to an AI KG, is not used. However, we still include information 
about this initiative in this review because the results of this approach are exactly in line 
with the goals of a KG. The living mapping of trials registered on the WHO platform is 
updated weekly and contained 2358 randomized control trials (RCTs) at the end of 2020. 
The living synthesis of published trials, including both articles and preprints, is updated 
daily, and contained 157 RCTs with results at the end of 2020. The highly interactive data 
visualizations that have been developed as a result of this initiative constitute some of the 
most useful summaries of COVID-19 research. Some examples are shown in Figures 4–6, 
but to fully appreciate the flexibility provided by the visualization tools, we encourage 
the reader to visit the website. Potentially this high-quality human curation can be re-
placed in the future by AI to ensure sustainability.  
 
Figure 4. Trend of number of trials registered by treatment name. Taken from https://covid-nma.com/dataviz (accessed 
on 25 March 2021). 
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Figure 5. The diagram on the right describes the network of randomized control trials (RCTs) evaluating pharmacologic 
treatments for COVID-19 which fulfill criteria that the user selects. The nodes in the diagrams represent the different 
treatments evaluated in these RCTs and the lines represent the direct comparisons made in the studies. When two nodes 
are connected with a line, it means there is at least one study that compares the corresponding treatments, whereas when 
they are not connected, it means there is no study comparing them. The size of the nodes is proportional to the number of 
participants allocated to each intervention and the thickness of the lines is proportional to the number of studies that 
compare each pair of treatments. Taken from https://covid-nma.com/dataviz (accessed on 23 February 2021). 
 
Figure 6. A forest plot comparing two interventions chosen by the user, in this case tocilizumab and placebo/standard of 
care. Taken from https://covid-nma.com/dataviz (accessed on 23 February 2021). 
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3.4. Multi-Purpose Knowledge Graphs 
We found three papers that use KGs for multiple tasks, including literature search 
and drug repurposing. The first, by Chen et al. [30], carried out a case study on the appli-
cation possibilities of KGs. The introduction of their paper provides an excellent history 
of the emergence of KGs in the field of AI, which we summarize in the rest of this para-
graph. They point out that in the past, KGs have been curated manually, but the move 
towards natural language understanding through semantic technologies has accelerated 
in the past decade, promoting named entity recognition (NER) to a central NLP task. NER 
has been crucial for building and constructing KGs as the primary method of analyzing 
free text to extract entities and possibly relations. Additionally, tasks such as link predic-
tion, relation extraction, and graph completion on KGs are aided by NER. In the early 
2000s, biomedical NER relied on feature engineering and graphical models such as hidden 
Markov models (HMMs) and conditional random fields (CRFs), which had poor accuracy 
compared to the current state-of-the art which uses deep learning. Bidirectional Encoder 
Representations from Transformers (BERT [31]) is the foundational work from Google 
that has made deep-learning-based NER possible. BioBERT [32] is a biomedical language 
representation model based on BERT used by the authors to mine the CORD-19 dataset, 
as well as the PubMed database and PubMed KG.  
To illustrate the utility of KGs, the authors performed several experiments, the most 
basic of which was compiling a list of most-published authors in the CORD-19 dataset. In 
an experiment using BioBERT, they found that BioBERT can easily recognize the common 
bio-entities with a high occurrence rate in the corpus but fails to recognize rare biomedical 
terms. They used two metrics to find the strength of KG associations, i.e., weights, be-
tween source and target nodes: co-occurrence frequency and cosine similarity. Figure 7 
shows KGs related to remdesivir based on co-occurrence frequency. They state that while 
this is a promising approach, a major limitation of co-occurrence frequency is that it can-
not reflect the relationship between the source node and the target node well. For exam-
ple, if “A has nothing to do with B” is mentioned often in documents, its co-occurrence 
frequency will be high. Cosine similarity has the benefit of being a normalized metric un-
like co-occurrence frequency, but it still has the same limitation. 
 
Figure 7. Remdesivir-related KGs: associated diseases (left) and associated drugs (right) based on co-occurrence frequency. 
Reproduced with permission from Chen et al. [30]. 
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The second paper, by Reese et al. [33], is a framework for producing KGs that can be 
customized for downstream applications including machine learning tasks, hypothesis-
based querying, and browsable user interface. For example, a drug repurposing applica-
tion would make use of protein data linked with approved drugs, while a biomarker ap-
plication could utilize data on gene expression linked with pathways. The authors explain 
that researchers are confronted with a number of technical challenges when trying to use 
existing data to discover actionable knowledge about COVID-19, which we summarize in 
the rest of this paragraph. The data needed to address a given question are typically siloed 
in different databases and employ different identifiers, data formats, and licenses. For ex-
ample, to examine the function of proteins targeted by FDA-approved antiviral drugs, one 
must download and integrate drug, drug target, and FDA approval status data (from 
Drug Central, for example, in a bespoke TSV format) and functional annotations (from, 
for example, Gene Ontology in GPAD format). Furthermore, many datasets are updated 
periodically, which requires researchers to re-download and re-harmonize data. KGs are 
a way of representing and integrating heterogeneous data and their interrelationships us-
ing a hierarchical system such as an ontology. This kind of representation is amenable to 
complex queries, e.g., “which drugs target a host protein that interacts with a viral pro-
tein?”, and also to graph-based machine learning techniques. 
Their workflow is divided into three steps: data download (fetch the input data), 
transform (convert the input data to KGX interchange format), and merge (combine all 
transformed sources). The ingested data are focused on sources relevant to drug repur-
posing for downstream querying and machine learning applications, prioritizing drug 
databases, protein interaction databases, protein function annotations, COVID-19 litera-
ture, and related ontologies. From the final merged graph, training and test data sets suit-
able for machine learning applications are created. Embiggen, their implementation of 
node2vec and related algorithms, is applied to this KG to generate embeddings, vectors 
in a low dimensional space which capture the relationships in the KG. Embiggen is trained 
iteratively to identify optimal node2vec hyperparameters (walk length, number of walks, 
p etc.) and to then train classifiers, e.g., logistic regression, random forest, support vector 
machines, that can be used for link prediction. The trained classifiers can then be applied 
to produce actionable knowledge: drug to disease links, drug to gene links, and drug to 
protein links. Besides machine learning, the authors have also used the KG for hypothesis-
based querying. For example, they have queried the KG to identify host proteins that are 
known to interact with viral proteins, and these are further filtered according to whether 
these host proteins are targets of approved drugs. In the framework created by the au-
thors, each data source is transformed and output as a separate graph, which is later com-
bined with graphs for other data sources according to the needs of the user. They explain 
that although the subgraphs from the various data sources, e.g., Drug Central, are pro-
duced locally by their framework, they could easily incorporate graphs generated by other 
researchers. The exchange of data via a ‘KG-Hub’ would eliminate the duplication of ef-
fort that occurs when researchers separately transform and prepare data and might also 
facilitate the formation of a data sharing portal. 
The third article, by Ostaszewski et al. [34], describes a large-scale community effort 
to build an open-access, interoperable, and computable repository of SARS-CoV-2 virus–
host interaction mechanisms. They discuss the tools, platforms, and guidelines necessary 
for the distributed development of this Disease Map (a constantly evolving collection of 
machine-and-human-readable computational diagrams and models of molecular mecha-
nisms implicated in the disease) by a community of biocurators, domain experts, bioin-
formaticians, and computational biologists. Biocurators develop a collection of systems 
biology diagrams focused on the molecular mechanisms of SARS-CoV-2. Domain experts 
refine the contents of the diagrams, supported by interactive visualization and annota-
tions. Using interaction and pathway databases (which contain structured and annotated 
information on protein interactions or causal relationships) and text mining, they enrich 
and validate the curated mechanisms. The authors use text mining and pathway figure 
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mining, i.e., decoding pathway figures into their computable representations, to create 
KGs, which they define as “semantic networks incorporating ontology concepts, unique 
biomolecule references, and their interactions extracted from abstracts or full-text docu-
ments”. Biocurators can then use this content: by visual exploration, by programmatically 
querying the KGs, and by direct incorporation of the content after converting to the ap-
propriate file format. Bioinformaticians and computational biologists develop computa-
tional workflows to generate hypotheses and predictions about the mechanisms encoded 
in the diagrams. The Disease Map provides a platform for a precise formulation of mech-
anistic models, accurate data interpretation, monitoring of therapy, and potential for drug 
repositioning. 
3.5. Knowledge Graphs for Risk Factor Discovery 
We found only one paper of this type, and thus feel this is an under-explored appli-
cation of KGs. Bettencourt-Silva et al. [35] present a pipeline to discover COVID-19 health 
outcomes and related social factors based on trending social determinants of health 
(SDoH) at population-level using Google Trends. SDoH are the factors which lie outside 
of the traditional health system, such as employment or access to nutritious foods, that 
influence health outcomes. The authors point out that electronic health record systems 
have not traditionally been designed to capture SDoH-related data and healthcare termi-
nologies such as ICD-10 (10th revision of the International Statistical Classification of Dis-
eases and Related Health Problems, a medical classification list by the World Health Or-
ganization) or SNOMED-CT (Clinical Terms defined by SNOMED International, an inter-
national non-profit standards development organization) may not extensively cover so-
cial concepts. A WHO-defined set of SDoH keywords was monitored using Google 
Trends. Specific SDoH keywords were then identified by performing a statistical analysis 
of population data, e.g., keywords trending higher in a particular time period, i.e., Febru-
ary to April 2020, compared to historical data. Such keywords became seeded terms to be 
found as nodes in a KG of related concepts. Finding the nodes connected to the seeded 
terms by traversing the KG yielded additional nodes with insights of potentially relevant 
concepts to be investigated further. From the list of ten Google Topics, Unemployment and 
Food Insecurity were the two that peaked the most during the start of the pandemic and 
also saw their highest 5-year peaks in the same period. These two concepts were selected 
for the case study presented in this paper to illustrate the developed pipeline. 
Their KG was built by first mining co-occurring concepts, i.e., a pair of concepts, at 
least one of which is Unemployment or Food Insecurity, from the literature. Starting from 
the PubMed database, the authors used MetaMap to tokenize and identify UMLS concepts 
in the sentences of the abstracts. They restricted the medical concepts to only those of the 
following UMLS semantic types: Disease or Syndrome, Individual Behavior, Mental or Behav-
ioral Dysfunction. These concepts seemed to be the most relevant to their aim of identifying 
potential socio-medical issues in the context of COVID-19. They filtered out of the results 
the sentences containing three concepts or more, which they believed would prove too 
difficult to use to extract accurate pairwise relations. To extract relations between a con-
cept pair, they used a supervised sentence classification model, a fine-tuned BERT. To 
train the model, they sampled 550 of the context sentences and manually annotated them 
with five labels: positive if the concepts were found to be in positive correlation, negative 
for a negative correlation, complex for a more complex relation not easily classified as the 
first two (e.g., a relation conditioned on a specific characteristic of the population), nocor 
if the authors did not find a correlation, and N/A for sentences not expressing any state-
ment on the relation. A graph database was subsequently used to store, query, and visu-
alize the mined concepts. 
The results of their work can be seen in Figure 8, which shows the two SDoH dimension 
concepts and their most relevant neighbors based on relative frequency. The authors state 
that the most interesting nodes are the ones connected to both SDoH dimensions (e.g., Obe-
sity or Depression), and that such concepts should be closely monitored and analyzed in the 
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time period following the start of the pandemic. For example, a simple analysis of Google 
Trends (Worldwide) from May to June 2020 revealed peaks for Obesity (Google Trend class: 
medical condition) and Coping (topic) in May 2020 and for Anxiety (emotional disorder) in 
June. These examples show the largest interest recorded in the past 5 years. They explain 
that further work is needed to analyze these data, inspect other geographical levels (e.g., 
country), and understand the causes for the sudden rise in these concepts. Their proposed 
pipeline should have wider applicability in (a) identifying social or clinical characteristics of 
interest, (b) outbreak surveillance, or (c) mining relations between social and health concepts 
that can help inform and support citizen-centered services. 
 
Figure 8. Two social determinants of health (SDoH) dimension concepts (Unemployment and Food Insecurity) and their most 
relevant neighbors based on relative frequency. Reproduced with permission from Bettencourt-Silva et al. [35]. 
4. Discussion 
To our knowledge, this is the first exploratory review focusing on KGs that are used 
to accelerate COVID-19 research. We found KGs being put to different uses, with typically 
multiple publications per use. In addition, we provided detailed summaries of the meth-
odologies that were used in these publications, making this article interesting not only for 
researchers and clinicians focusing on COVID-19, but also readers interested in imple-
menting KGs in other domains, including other diseases which have a high volume of 
research output being generated. 
A seeming limitation of this study is that the papers that correspond to the same ap-
plication group are not compared quantitatively. However, this arises due to the nature 
of the papers themselves. When trying to evaluate the pros and cons of different ap-
proaches that are trying to address the same need, e.g., a literature search using KGs, it is 
important to have agreed upon benchmarks in terms of datasets used and performance 
metrics. Such benchmarks do not exist yet, in the absence of which we are forced to com-
pare methods based mainly on methodology. While methodological differences between 
two approaches can be obvious, the impact that such differences will have on performance 
cannot be gauged without actually using the methods, which is beyond the scope of this 
work. Furthermore, the choice of the “best” approach may depend on the end user; for 
example, when choosing the right search engine to conduct a literature search, if the end 
user is a developer, they could prefer the approach that offers open-source code that the 
developer can use as a starting point. If the end user is a clinician, they might prefer the 
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approach that is more user-friendly and offers more relevant results. Keeping these cave-
ats in mind, we now present a comparative assessment of the papers that belong to the 
same application group, i.e., literature search, drug repurposing, and multi-purpose. Clin-
ical trial mapping and risk factor analysis are excluded from this discussion, as we only 
found one effort each for these uses. 
4.1. Knowledge Graphs for Literature Search 
Four papers were reported under this application group: Steenwinckel et al. [5], Wise 
et al. [14], Cernile et al. [18], and Michel et al. [19]. All of these papers used the CORD-19 
dataset; [14,18] use proprietary code, whereas [5,19] have made their code open-source 
and followed FAIR principles. While [5,14,19] mentioned clustering analysis, there is no 
way to judge based on these publications which clustering approach is most effective. To 
identify influential publications, ref. [5] measured node centrality; ref. [14] measured pop-
ularity. To identify similar papers, ref. [5] used nearest neighbors on RDF2vec embed-
dings, whereas [14], besides using SciBERT embeddings, also defined novel metrics such 
as topic and citation similarity. Again, there is no way to assess which approach would be 
more beneficial to a user. As mentioned previously, a unique and useful feature of [19] is 
ACTA, which allows the creation of argumentative graphs and identifying PICO ele-
ments. Surprisingly, the authors of [19] did not include any results in their publication 
showing the utility of such argumentative graphs, for example, by surveying a group of 
clinicians and reporting their user experience. When we used ACTA to check its PICO 
identification capability, we found qualitatively that it performs well at identifying the 
PICO elements, except for the P (patients/population) element. We are unsure whether 
this is because the publicly available search engine does not utilize the latest version of 
their code, or because ACTA is not trained to detect the P element. 
During the peer review process, we were made aware of a paper by Giarelis et al. 
[36] that is more rigorous in its performance evaluation than the papers included in this 
review. It was not found in our search, as it is not indexed on PubMed, and our Google 
and Google Scholar searches were limited to the first 50 results. The paper uses KGs to 
address the problem of discovering future research collaborations. The authors treat it as 
a binary classification problem, which allows them to report standard metrics such as ac-
curacy, precision, and recall. A sample is labeled as positive or negative depending on the 
presence or absence of a co_authors edge between two Author nodes. For all their perfor-
mance evaluation experiments, they used subsets of the CORD-19 dataset, which is the 
obvious choice for a benchmark dataset. Using such a standard dataset to address a well-
defined question and reporting widely used performance metrics would make quantita-
tive comparisons between papers possible. 
4.2. Knowledge Graphs for Drug Repurposing 
Five papers were included in this application group: Stebbing et al. [21], Wang et al. 
[23], Domingo-Fernandez et al. [24], Hsieh et al. [25], and Zhou et al. [26]; the last of these 
is a review article. Stebbing et al. [21] is a comment article that focuses on a proprietary AI 
algorithm. The article makes the output of the AI algorithm explainable: using clear logic 
that dispels any notions of a black box, the authors justify why baricitinib should be an 
effective treatment for COVID-19, a claim that has been verified in a clinical trial. How-
ever, as the algorithm is proprietary, there is no explanation about how it works. Wang et 
al. [23] is the only paper in this review that talks about drug repurposing report genera-
tion. The content of such an AI-generated drug report, mentioned in Section 3.2, is very 
useful to understand why a drug repurposing candidate was chosen. The paper mentions 
that the reports were reviewed by clinicians and medical students, but a more quantitative 
appraisal will perhaps be available at a later stage. The paper is also unique in using figure 
images from publications to enrich their KG. 
The most notable feature of the KG in [24] is that it is human-curated. While the pre-
sent-day superiority of human curation is hard to deny, it is noteworthy that their KG 
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only contains information from 160 original research articles. It is unclear whether human 
curation would be sustainable if this number were one or two orders of magnitude higher. 
Their method was able to identify over 300 candidate drugs being investigated to treat 
COVID-19. By contrast, ref. [25] starts by considering all drugs (n = 3635) being investi-
gated for COVID-19 treatment. Another key difference between [24] and [25] is that [24] 
uses a web application to allow users to query, browse, and navigate their KG, whereas 
[25] presented a list of top repurposable drugs. As a result, ref. [25] seems more lay-user-
friendly, but that does not mean that its top-ranked drugs will actually be effective treat-
ments for COVID-19. 
4.3. Multi-Purpose Knowledge Graphs 
Three papers were included in this application group: Chen et al. [30], Reese et al. 
[33], and Ostaszewski et al. [34]. Chen et al. [30] discussed four experiments in their paper: 
identifying experts on coronavirus topics for building collaborations, named entity recog-
nition with BioBERT, co-occurrence frequency-based KG, and cosine similarity-based KG. 
Their results for BioBERT showed a named entity recognition that is far worse than hu-
man (best F1-scores around 0.75) but had the advantage of parsing far more documents 
than humanly possible. It is unclear if this trade-off is worthwhile. While their two KG 
experiments can be used for drug repurposing and produces pleasing figures, an example 
of which is shown in Figure 7, that approach is far less sophisticated than some of the 
papers mentioned under the drug repurposing application group [23–25]. 
Reese et al. [33] downloaded data from multiple siloed and incompatible data sources 
before converting and combining them using the KGX interchange format. It is unclear 
why KGX is not a more widely used format: it was not mentioned in any of the other 
papers included in this review, despite offering the advantage of combining features of 
RDF and property graphs. To create KG embeddings, they used Embiggen instead of the 
more widely used RDF2vec. As a manuscript describing Embiggen is in preparation, it is 
not possible for us to evaluate its potential advantages over RDF2vec. The authors used 
these embeddings to address the machine learning problem of link prediction: drug to 
disease, drug to gene, and drug to protein. While they qualitatively showed the utility of 
their approach using t-SNE plots, no quantitative results using metrics such as accuracy 
or F1-score were presented. 
Ostaszewski et al. [34] summarized the massive effort undertaken by the COVID-19 
Disease Map community to create an open-access collection of curated computational di-
agrams and molecular mechanisms models implicated in COVID-19. The Disease Map is 
a collection of 41 such diagrams containing 1836 interactions between 5499 elements, sup-
ported by 617 articles. While the authors do create KGs, they mention that KGs have a 
broad coverage at the cost of depth of mechanistic interpretation. Hence, the goal of these 
KGs is to allow biocurators to enrich the previously mentioned pathway diagrams, mak-
ing human–machine collaboration a reality. The end users of such diagrams are bioinfor-
maticians and computational biologists, rather than clinicians. 
5. Conclusions 
In this work, we have provided an exploratory review on KGs in the context of 
COVID-19. By providing links between disparate datasets that are stuck in silos, KGs en-
able the user to effectively search the overwhelming volume of COVID-19 research and 
gain actionable insight which would either be extremely tedious or impossible to achieve 
in the absence of such emerging uses of AI. We believe that in these early days of KGs, it 
is difficult to fully assess the potential of each work, as the results they have presented are 
in most cases preliminary. We see the main contribution of our paper as being a detailed 
summary of various approaches rather than their ultimate performance, with the aim of 
raising awareness of the technology behind KGs. 
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